NCT07058948 (SFRT-IM-P2) is a Phase 2 clinical trial of lattice radiation therapy in Solid Cancers, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT07058948?

NCT07058948 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT07058948?

Interventions in NCT07058948: lattice radiation therapy.

What condition does NCT07058948 study?

NCT07058948 studies Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer.

Is NCT07058948 still recruiting?

NCT07058948 is currently recruiting now. Last updated 17 July 2025.

Last reviewed 2025-07-17 · How we verify

NCT07058948: SFRT-IM-P2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

Recruiting now Phase 2 Last updated 17 July 2025

What this trial tests

Phase 2 trial testing lattice radiation therapy in Solid Cancers in 30 participants. Currently enrolling.

Timeline

1 July 2025

Primary endpoint
1 July 2026

1 July 2027

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 July 2025
Primary completion	1 July 2026
Estimated completion	1 July 2027
Sites	1 location across China

Drugs / interventions tested

lattice radiation therapy

Conditions studied

Solid Cancers — all drugs for Solid Cancers →
Radiotherapy — all drugs for Radiotherapy →
Immune Checkpoint Inhibitor — all drugs for Immune Checkpoint Inhibitor →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

18 and older, any sex, with Solid Cancers or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lattice radiation therapy (LRT) is a spatially fractionated radiotherapy technique that creates alternating high - and low - dose areas within a tumor to enhance local control and reduce toxicity to surrounding tissues. This study aims to evaluate the effectiveness and safety of combining LRT with immunotherapy in patients with advanced or metastatic solid tumors, through a Phase II clinical trial. Patients will receive specific - dose irradiation using a medical linear accelerator. Within the GTV of the largest tumor, spheres (0.5 - 3 cm in diameter) will be created as high - dose targets (LRT targets), spaced 2.0 - 5.0 cm apart. The LRT targets must be drawn within the GTV, avoiding blood vessels, with a margin of at least 1 cm from the GTV margin, and a volume ratio of 1% - 10% of the GTV. For a single lesion, the D95 of the GTV will be ≥1 Gy/fraction, and the D95 of the LRT target will be 8 - 12 Gy/fraction, with minimal possible single - fraction doses to organs at risk. All other irradiated metastases will receive low - dose radiotherapy (100 - 300 cGy × 5 fractions), except for brain and bone metastases, which will be treated with palliative radiotherapy as per clinical routine. Immunotherapy will be administered during or within one week after radiotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Cancers

Currently open trials in the same condition.

NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
NCT07479667 — An Antibody-armored Dendritic Cell in Patients With Solid Tumors · Phase 1 · recruiting
NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
NCT06883539 — A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. · Phase 1 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07058948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 17 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07058948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing